After more discontinuations, a new deal brings in fresh blood.
ApexOnco Front Page
Recent articles
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.